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Migraine is probably the second most common pain dis-
order next to tension-type headache. The majority of mi-
graineurs have episodic attacks, but a small minority have
chronic migraine [1, 2]. Treatment options for chronic
migraine are sparse. Thus, clinical trials investigating new
treatment options are therefore endorsed in order to provide
evidence-based data.
Two double-blind, randomized, placebo-controlled
clinical trials for the treatment of chronic migraine with
onabotulinumtoxinA, the Phase III REarch Evaluating
Migraine Prophylaxis Therapy (PREEMPT) 1 and 2 as well
as the pooled data from the two trials were recently pub-
lished [3–5].
The introduction of the three onabotulinumtoxinA
papers describes the deﬁnition of chronic migraine
according to the criteria of the International Classiﬁcation
of Headache Disorders II (ICHD II) [6, 7].
The PREEMPT inclusion criteria for chronic migraine
were:
1. Migraine according to the ICHD II excluding hemi-
plegic migraine, basilar-type migraine, ophthalmople-
gic migraine and migrainous infarction.
2. C15 headache days within 28 days at baseline, with
each day consisting of C4 h of continuous headache
and with C50% of days being migraine or probable
migraine days.
Two of the PREEMPT exclusions criteria were:
1. Diagnosis of other primary or secondary headache
disorders.
2. Use of prophylactic medication within 28 days before
start of baseline.
At a ﬁrst glance it seems that chronic migraine in the
PREEMPT studies adhere to criteria of the ICHD II, as
other primary and secondary headache disorders were
excluded. However, the latter was not speciﬁed in details
and also lacked a reference, although one might get the
impression that the criteria of the ICHD II were applied,
since this classiﬁcation is mentioned in the beginning of the
study participants section [3, 4]. However, Table 1 in the
results section shows that approximately 2/3 of all PRE-
EMPT 1 and 2 included participants with chronic migraine
had overused acute headache pain medication at baseline
[3, 4]. The pooled data publication do not include this
information in Table 1, but the result section mention that
most patients overused acute pain medication at baseline
and 1.7% had opioid overuse [5]. The mean years since
onset of chronic migraine varied between 17.6 and
20.6 years [3, 4]. Thus, it is reasonable to assume that the
medication overuse had persisted for at least 3 months in
the majority of the included participants with medication
overuse at baseline. According to the criteria of the ICHD
II chronic migraine is classiﬁed only if there is no medi-
cation overuse (criteria D) [6, 7]. Thus, the 2/3 of the
PREEMPT 1 and 2 included participants with chronic
migraine and medication overuse should be classiﬁed
medication overuse headache and not chronic migraine [6–
8]. This leaves only approximately 1/3 of PREEMPT 1 and
2 participants included with a ICHD II diagnosis of chronic
migraine. In fact it might be less, since the ICHD II
deﬁnition of chronic migraine only includes migraine
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siﬁcation on chronic migraine and medication overuse
headache has been a challenge within the last two decades,
since the ICHD I from 1988 did not include chronic
migraine, and the ICHD II from 2004 was soon revised [6–
9]. This has been described in details elsewhere [10].
However, the description of different chronic migraine
criteria in different part of the three onabotulinumtoxinA
papers are confusing and misleading, especially since
medication overuse is not explicit mentioned in the meth-
ods section (study participants sections) [3–5].
The heterogeneity of the study participants raise ques-
tions in relation to efﬁcacy of onabotulinumtoxinA on the
primary and secondary end point deﬁned in the PREEMPT
1 and 2. Firstly, what is the efﬁcacy of onabotulinumtox-
inA in those with medication overuse headache (chronic
migraine without aura and medication overuse headache)?
Secondly, what is the efﬁcacy of onabotulinumtoxinA in
those with chronic migraine (chronic migraine without aura
without medication overuse)? Furthermore, how do factors
such as migraine with aura, gender, race and previously
used prophylactic medication inﬂuence on the efﬁcacy of
onabotulinumtoxinA? Such evidence-based data are war-
ranted for those treating chronic migraine and medication
overuse headache.
Data on those whom had medication overuse headache
and those whom had previously tried prophylactic medi-
cation are especially important. Short information to peo-
ple with chronic headache (C15 days/month for at least
3 months) and medication overuse about the possible role
of medication overuse in headache chroniﬁcation, and no
further contact before follow-up approximately 1 years
later, reduced mean medication days from 22 to 6 days/
month, and 42% no longer had chronic headache [11].
Fifty-three percentage of the participants had co-occur-
rence of migraine, but only a few had chronic migraine.
Since enrollment of the PREEMPT 1 and 2 required that
prophylactic medication was not taken 28 days prior to the
baseline data collection, it is likely to assume that those
enrolled had none or only a modest effect of previous tried
prophylactic medications. This is important in the light that
79% (-6.6/-8.4) of the reduction of headache days (pri-
mary efﬁcacy variable) was due to placebo response [5].
Hopefully, future publication on onabotulinumtoxinA will
enlighten us regarding the efﬁcacy of onabotulinumtoxinA
for the treatment of chronic migraine and medication
overuse headache among others.
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